Back to search results

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

Abroad (travel likely)RecruitingPHASE3

Conditions

Neovascular Age-Related Macular Degeneration (nAMD) · Wet AMD

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Adverum Clinical Site 245, Mesa, Arizona, United States

  • Adverum Clinical Site 126, Phoenix, Arizona, United States

  • Adverum Clinical Site 178, Phoenix, Arizona, United States

  • Adverum Clinical Site 223, Phoenix, Arizona, United States

  • Adverum Clinical Site 229, Scottsdale, Arizona, United States

  • Adverum Clinical Site 242, Sun City, Arizona, United States

  • Adverum Clinical Site 198, Springdale, Arkansas, United States

  • Adverum Clinical Site 109, Bakersfield, California, United States

  • Adverum Clinical Site 100, Beverly Hills, California, United States

  • Adverum Clinical Site 201, Campbell, California, United States

  • Adverum Clinical Site 172, Encino, California, United States

  • Adverum Clinical Site 169, Fullerton, California, United States

  • Adverum Clinical Site 224, Huntington Beach, California, United States

  • Adverum Clinical Site 130, Poway, California, United States

  • Adverum Clinical Site 215, Redlands, California, United States

  • Adverum Clinical Site 140, Sacramento, California, United States

  • Adverum Clinical Site 212, Sacramento, California, United States

  • Adverum Clinical Site 175, Santa Barbara, California, United States

  • Adverum Clinical Site 202, Torrance, California, United States

  • Adverum Clinical Site 189, Walnut Creek, California, United States

  • Adverum Clinical Site 200, Denver, Colorado, United States

  • Adverum Clinical Site 116, Denver, Colorado, United States

  • Adverum Clinical Site 165, Waterford, Connecticut, United States

  • Adverum Clinical Site 124, Deerfield Beach, Florida, United States

  • Adverum Clinical Site 184, Deerfield Beach, Florida, United States

  • Adverum Clinical Site 176, Fort Lauderdale, Florida, United States

  • Adverum Clinical Site 221, Fort Myers, Florida, United States

  • Adverum Clinical Site 236, Gainesville, Florida, United States

  • Adverum Clinical Site 214, Lakeland, Florida, United States

  • Adverum Clinical Site 168, Miami Springs, Florida, United States

  • Adverum Clinical Site 213, Orlando, Florida, United States

  • Adverum Clinical Site 206, Plantation, Florida, United States

  • Adverum Clinical Site 183, South Miami, Florida, United States

  • Adverum Clinical Site 120, St. Petersburg, Florida, United States

  • Adverum Clinical Site 148, Tampa, Florida, United States

  • Adverum Clinical Site 238, Winter Haven, Florida, United States

  • Adverum Clinical Site 182, Augusta, Georgia, United States

  • Adverum Clinical Site 246, Chicago, Illinois, United States

  • Adverum Clinical Site 179, Oak Forest, Illinois, United States

  • Adverum Clinical Site 207, Oak Park, Illinois, United States

  • Adverum Clinical Site 195, Carmel, Indiana, United States

  • Adverum Clinical Site 205, Carmel, Indiana, United States

  • Adverum Clinical Site 253, Carmel, Indiana, United States

  • Adverum Clinical Site 197, Hagerstown, Maryland, United States

  • Adverum Clinical Site 204, Hagerstown, Maryland, United States

  • Adverum Clinical Site 216, Jackson, Mississippi, United States

  • Adverum Clinical Site 240, Bloomfield, New Jersey, United States

  • Adverum Clinical Site 171, Teaneck, New Jersey, United States

  • Adverum Clinical Site 225, Liverpool, New York, United States

  • Adverum Clinical Site 244, Rochester, New York, United States

  • Adverum Clinical Site 196, Asheville, North Carolina, United States

  • Adverum Clinical Site 234, Cary, North Carolina, United States

  • Adverum Clinical Site 211, Greensboro, North Carolina, United States

  • Adverum Clinical Site 219, Greensboro, North Carolina, United States

  • Adverum Clinical Site 220, Hickory, North Carolina, United States

  • Adverum Clinical Site 209, Wake Forest, North Carolina, United States

  • Adverum Clinical Site 248, Beachwood, Ohio, United States

  • Adverum Clinical Site 247, Cleveland, Ohio, United States

  • Adverum Clinical Site 254, Edmond, Oklahoma, United States

  • Adverum Clinical Site 252, Portland, Oregon, United States

  • Adverum Clinical Site 181, Erie, Pennsylvania, United States

  • Adverum Clinical Site 239, Philadelphia, Pennsylvania, United States

  • Adverum Clinical Site 110, Philadelphia, Pennsylvania, United States

  • Adverum Clinical Site 241, Bluffton, South Carolina, United States

  • Adverum Clinical Site 222, Ladson, South Carolina, United States

  • Adverum Clinical Site 101, Nashville, Tennessee, United States

  • Adverum Clinical Site 145, Arlington, Texas, United States

  • Adverum Clinical Site 127, Austin, Texas, United States

  • Adverum Clinical Site 243, Austin, Texas, United States

  • Adverum Clinical Site 107, Conroe, Texas, United States

  • Adverum Clinical Site 194, Dallas, Texas, United States

  • Adverum Clinical Site 162, McAllen, Texas, United States

  • Adverum Clinical Site 185, San Antonio, Texas, United States

  • Adverum Clinical Site 232, San Marcos, Texas, United States

  • Adverum Clinical Site 228, Schertz, Texas, United States

  • Adverum Clinical Site 231, The Woodlands, Texas, United States

  • Adverum Clinical Site 237, Tyler, Texas, United States

  • Adverum Clinical Site 199, Lynchburg, Virginia, United States

  • Adverum Clinical Site 249, Silverdale, Washington, United States

Study leads

  • Adam Turpcu, PhD

    Study Director

    Adverum Biotechnologies, Inc.

View source on ClinicalTrials.gov(opens in a new tab)